Adding Daratumumab to Lenalidomide and Dexamethasone Beneficial in Multiple Myeloma

Share this content:
Daratumumab with lenalidomide and dexamethasone was superior for progression-free survival of patients with relapsed or refractory multiple myeloma.
Daratumumab with lenalidomide and dexamethasone was superior for progression-free survival of patients with relapsed or refractory multiple myeloma.

Daratumumab with lenalidomide and dexamethasone was superior to lenalidomide plus dexamethasone for progression-free survival of patients with relapsed or refractory multiple myeloma, according to a study presented at the European Hematology Association (EHA) 21st Congress.1

For this phase 3 POLLUX trial, investigators enrolled 569 patients with multiple myeloma who had received at least 1 prior line of therapy. Participants were randomly assigned 1:1 to receive lenalidomide and dexamethasone with or without daratumumab, a human anti-CD38 IgG monoclonal antibody.

With a median follow-up of 13.5 months, results showed that adding daratumumab reduced the risk of progression or death by 63% (hazard ratio, 0.37; 95% CI, 0.27-0.52; P < .0001).

Addition of daratumumab to lenalidomide and dexamethasone also prolonged time to progression (hazard ratio, 0.34; 95% CI, 0.23-0.48; P < .0001) and improved the overall response rate (93% versus 76%; P < .001).

Daratumumab-associated infusion-related reactions, which were reported in nearly half of daratumumab-treated patients, were mostly grade 1 to 2; 92% occurred during the first infusion.

RELATED: Outcomes in Pretreated, Refractory Multiple Myeloma Remain Poor

Similar rates of treatment discontinuation due to treatment-emergent adverse events were observed between the 2 groups.                                    

Reference

  1. Dimopoulos MA, Oriol A, Nahi H, et al. An open-label, randomised phase 3 study of daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): POLLUX. Paper presented at: European Hematology Association 21st Congress; June 9-12, 2016; Copenhagen, Denmark.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs